Stocks · News reference

Hims & Hers On FTC Lawsuit, Says Lawsuit Disregards Substantial Evidence We Provided The FTC During Its Nearly Three-Year Investigation; We Are Confident In Our Position And Will Vigorously Defend Ourselves Against These Baseless Claims

Jul 29, 2026, 5:26 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 26, 2026, 10:47 AMBenzinga Newsdesk
Eli Lilly Announces Results From Real-World Study Of Overweight Or Obese Adults Over 55 Indicating That Staying On Zepbound For Weight Management Lowered Healthcare Costs Over Time
For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lower costs translate into meaningful savings as early as 12 months into treatment. This is the first study of its kind in
Read original at benzinga
HIMS LLY NVO
BenzingaAug 24, 2026, 5:20 PMBenzinga Newsdesk
Truist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $32
Truist Securities analyst Jailendra Singh maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $27 to $32.
Read original at benzinga
HIMS
BenzingaAug 21, 2026, 3:11 PMBenzinga Newsdesk
Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35
Barclays analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and lowers the price target from $39 to $35.
Read original at benzinga
HIMS
BenzingaAug 19, 2026, 4:32 PMVandana Singh
Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access
Hims & Hers CEO Andrew Dudum defends the firm against an FTC lawsuit, discusses dropping GLP-1 drug prices and reveals in-house AI plans.
Read original at benzinga
HIMS META NVO SNAP